Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FHTX vs DSGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DSGN Captures Overall Composite Edge (49.8 HOLD vs 35.3 SELL), While FHTX Leads 6–0 on Growth & Valuation Pillars

DSGN Overall Winner 6-Pillar Tally: FHTX 6 – 0 DSGN Matrix Metrics: FHTX 4 – 5 DSGN

As of Nov 16, 2026, Design Therapeutics, Inc. (DSGN) captures the overall head-to-head institutional edge over Foghorn Therapeutics Inc. (FHTX) on higher Unified Composite conviction (49.8/100 HOLD vs. 35.3/100 SELL) after splitting the core matrix 5–4 (led by composite factor balance), while FHTX wins 6–0 across the 6-pillar growth and valuation breakdown. FHTX trades at $1.81 (N/M Forward P/E, 8.0% operating margin) versus DSGN at $9.94 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: DSGN earns the overall head-to-head edge with a stronger Unified Composite Score (49.8/100 HOLD vs. FHTX 35.3/100 SELL) and 1.32β · 61% Vol risk profile, whereas FHTX leads top-line expansion (+924.7% YoY revenue growth, N/M PEG, and 6 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: FHTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.8); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FHTX vs DSGN
FHTX NASDAQ
Foghorn Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$1.81
-12.56% 1D
Market Cap $122.9M
TTM Revenue $64M
Forward P/E N/M
Beta / 30D Vol 1.67β · 79% Vol
Unified Composite Score
35.3 / 100 SELL
Tech 10.0 Fund 47.0 Flow 50.0 Mom 74.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -38.5%), weak momentum, RSI 34
RSI-14: 33.8 · SMA20: $2.03 · SMA50: $2.72
DSGN NASDAQ Head-to-Head Winner
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-5.06% 1D
Market Cap $677.5M
TTM Revenue $33,000
Forward P/E N/M
Beta / 30D Vol 1.32β · 61% Vol
Unified Composite Score
49.8 / 100 HOLD
Tech 55.0 Fund 57.0 Flow 63.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.7%), weak momentum, RSI 40
RSI-14: 40.4 · SMA20: $10.53 · SMA50: $11.58

6-Pillar Scorecard Institutional Category Breakdown (FHTX 6 – 0 DSGN)

Columns: Metric · FHTX · DSGN
1. Valuation Multiples FHTX
Forward P/E N/M N/M
Trailing P/E 22.8x N/M
PEG Ratio N/M N/M
EV / Revenue 1.9x N/M
2. Growth & Scale FHTX
Revenue Growth (YoY) +924.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $64M $33,000
Market Cap $122.9M $677.5M
3. Profitability & Quality FHTX
Gross Margin 30.7% N/A
Operating Margin 8.0% 0.0%
Net Profit Margin 8.4% 0.0%
Return on Equity (ROE) -470.4% -36.9%
4. Balance Sheet & Cash Flow FHTX
Cash Generation (TTM) $6.0M EBITDA -$59M
Cash Flow Margin 9.3% EBITDA Mgn N/A
Net Cash / Leverage -470.4% ROE $13M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FHTX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 164.9% (34th %ile) 92.0% (13th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat FHTX
OpEx & R&D Intensity 22.7% of Rev ($15M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FHTX (4) vs DSGN (5)
Institutional Metric FHTX DSGN Criterion Row Edge
Market Capitalization
Scale
$122.9M $677.5M Larger Scale DSGN
Trailing P/E Ratio
Valuation
22.8x N/M Lower Multiple FHTX
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+924.7% +0.0% Higher Growth FHTX
Operating Margin (TTM)
Profitability
8.0% 0.0% Higher Margin FHTX
Net Profit Margin
Profitability
8.4% 0.0% Higher Margin FHTX
Return on Equity (ROE)
Capital Efficiency
-470.4% -36.9% Higher ROE DSGN
52-Week Range Position
Momentum
0% ($2–$8) 30% ($7–$17) Stronger Trend DSGN
Beta / 30D Volatility
Risk Regime
1.67β · 79% Vol 1.32β · 61% Vol Lower Realized Risk DSGN
Unified Institutional Score
Composite Signal
35.3 / 100 (SELL) 49.8 / 100 (HOLD) Higher Composite DSGN
Trailing 12M Revenue (USD)
Operating Scale
$64M $33,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
30.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$6.0M EBITDA (-470.4% ROE) -$59M ($13M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FHTX +1.43 pp
FHTX: -2.16% · DSGN: -3.59%
3M Horizon DSGN +38.28 pp
FHTX: -73.19% · DSGN: -34.91%
6M Horizon DSGN +45.52 pp
FHTX: -52.62% · DSGN: -7.1%
1Y Horizon DSGN +99.28 pp
FHTX: -58.49% · DSGN: +40.79%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FHTX vs DSGN. Trailing 12-month operating profitability (FHTX 8.0% vs DSGN 0.0%) and valuation multiples (FHTX N/M vs DSGN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

FHTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$64M
Gross Margin30.7%
Op. Margin8.0%
ROE / Fwd P/E-470.4% · N/M
DSGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$33,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-36.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FHTX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 164.9%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FHTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DSGN BREAKDOWN
139d in phase · OBV NEUTRAL
Current IV 92.0%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DSGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FHTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $122.9M market capitalization and 8.0% operating margin.
OpEx & R&D Reinvestment 22.7% of Rev ($15M)
90D Engineering Disclosures 0 Published
DSGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FHTX vs DSGN Key Questions & Quantitative Answers

As of Nov 16, 2026, Design Therapeutics, Inc. (DSGN) captures the overall head-to-head institutional edge over Foghorn Therapeutics Inc. (FHTX) on higher Unified Composite conviction (49.8/100 HOLD vs. 35.3/100 SELL) after splitting the core matrix 5–4 (led by composite factor balance), while FHTX wins 6–0 across the 6-pillar growth and valuation breakdown. FHTX trades at $1.81 (N/M Forward P/E, 8.0% operating margin) versus DSGN at $9.94 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: DSGN earns the overall head-to-head edge with a stronger Unified Composite Score (49.8/100 HOLD vs. FHTX 35.3/100 SELL) and 1.32β · 61% Vol risk profile, whereas FHTX leads top-line expansion (+924.7% YoY revenue growth, N/M PEG, and 6 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: FHTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.8); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FHTX leads the Growth & Scale pillar: FHTX posts +924.7% YoY revenue growth and +0.0% YoY earnings growth on $64M TTM revenue (30.7% gross margin, 8.0% operating margin), compared with DSGN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, FHTX generates $64M in USD-normalized revenue versus $33,000 for DSGN. In operating R&D and SG&A reinvestment, FHTX deploys 22.7% of Rev ($15M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DSGN.

FHTX screens cheaper on headline valuation multiples. FHTX trades at N/M Forward P/E, 22.8x Trailing P/E, N/M PEG, and 1.9x EV/Revenue (9.3% EBITDA margin), whereas DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FHTX (-470.4% ROE) versus DSGN (-36.9% ROE) capital efficiency.

In options market volatility and institutional positioning, FHTX carries 164.9% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.67β · 79% Vol realized risk). By comparison, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.